



## L&G AXA Framlington Health Pn

### Fund objective

The aim of this Fund is to provide long-term capital growth.

### Detailed fund information

**Unit name** L&G AXA Framlington Health Pn

**FE fundinfo Crown Rating** 

**Sector** Specialist

**Domicile** United Kingdom

**Fund currency** GBX

**Unit currency** GBX

**Launch date** 20-Apr-2006

**Fund size** (as at 06-Feb-2026) £0.1m

**Primary asset class** Equity

**Inc / Acc** Accumulating

### Price and charges

**Bid price** (as at 06-Feb-2026) GBX 535.90

**Offer price** (as at 06-Feb-2026) GBX 535.90

**Initial charge** n/a

**Annual charge** 1.23%

### Codes

**Citicode** L168

**ISIN** GB00B0YTDK32

### Management information

**Fund manager** Cinney Zhang

**Start date** 29-Mar-2024

**Fund manager** Mr. Catherine Tennyson

**Start date** 29-Mar-2024

**Fund manager** Mr. Christopher Eccles

**Start date** 29-Mar-2024

**Address** One Coleman Street, London

**Tel** +44 (0) 20 3124 3277 (Main Number)

**Website** www.lgim.com

### Past performance overview fund vs. sector



05/02/2021 - 06/02/2026 Powered by data from FE fundinfo

### Cumulative performance (%)

	YTD	3m	6m	1y	3ys	5ys
L&G AXA Framlington Health Pn	-4.7	+0.2	+14.9	-4.5	+5.0	+20.5
Specialist	+1.3	+1.7	+7.0	+8.8	+22.2	+22.6

### Discrete performance (%)

	YTD	2025	2024	2023	2022	2021
L&G AXA Framlington Health Pn	-4.7	+5.8	+2.7	+1.6	+3.0	+15.5
Specialist	+1.3	+10.3	+6.5	+6.5	-8.7	+6.9

### Growth of £1000 over 3 years

Total return performance of the fund rebased to 1000. Your actual return would be reduced by the cost of buying and selling the fund, and inflation.




■ Fund

06/02/2023 - 06/02/2026 Powered by data from FE fundinfo

All prices in Pence Sterling (GBX) unless otherwise specified. Price performance figures are calculated on a bid price to bid price basis with net income (dividends) reinvested. Performance figures are shown in Sterling.


## Asset allocation

Key	Rank	Asset class	% of Fund (31.12.2025)
A	1	North American Equities	67.0
B	2	Europe ex UK Equities	25.1
C	3	UK Equities	7.0
D	4	Money Market	0.8




## Regional breakdown

Key	Rank	Region	% of Fund (31.12.2025)
A	1	North America	67.0
B	2	Europe Ex UK	25.1
C	3	UK	7.0
D	4	Cash	0.8



## Sector breakdown

Key	Rank	Sector	% of Fund (31.12.2025)
A	1	Life Sciences Tools & Services	39.1
B	2	Pharmaceuticals	29.5
C	3	Health Care Equipment	14.7
D	4	Managed Health Care	14.3
E	5	Health Care Facilities	1.7
F	6	Cash	0.8



## Top ten holdings

Rank	Holding	% of Fund (31.12.2025)
1	LILLY (ELI) & CO	7.7
2	ASTRAZENECA PLC	5.7
3	THERMO FISHER SCIENTIFIC INC.	4.4
4	NOVO NORDISK A/S	4.1
5	ROCHE HOLDING AG	4.1
6	EXACT SCIENCES CORPORATION	3.9
7	BOSTON SCIENTIFIC CORPORATION	3.4
8	INTUITIVE SURGICAL, INC.	3.4
9	ABBVIE INC.	3.1
10	SARTORIUS AKTIENGESELLSCHAFT	3.0